Retraction: Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-Cell Lymphoma (CTCL) cells (PLoS ONE (2011) 6:9 (e24849) DOI: 10.1371/journal.pone.0024849);Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell Lymphoma (CTCL) cells

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Marzec, Michal ^a   Liu, Xiaobin ^a   Wysocka, Maria ^a   Rook, Alain H ^a   Odum, Niels ^b   Wasik, Mariusz A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MNK1 KINASE; MNK2 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN MCL 1; S6 KINASE; SERINE; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MKNK1 PROTEIN, HUMAN; MTORC1 COMPLEX, HUMAN; PHOSPHOSERINE; PROTEIN; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DNA FRAGMENTATION; ENZYME ASSAY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NICK END LABELING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

EUKARYOTA; RAPTORES;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; EUKARYOTIC INITIATION FACTOR-4E; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOMA, T-CELL, CUTANEOUS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PHOSPHOSERINE; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; SIROLIMUS;

EID: 80052828293     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0239102     Document Type: Erratum

References (23)

1. Ciuffreda L, Di Sanza C, Incani UC, Milella M, (2010) mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets 10: 484-495.
2. Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, et al. (2010) mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328: 1172.
3. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R, (2004) Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of leukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol pp. 6539-6549.
4. Hwang ST, Janik JE, Jaffe ES, Wilson WH, (2008) Mycosis fungoides and Sézary syndrome. Lancet 371: 945-957.
5. Marzec M, Liu X, Kasprzycka M, Witkiewicz A, Raghunath PN, et al. (2008) IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood 111: 2181-2189.
6. Marzec M, Kasprzycka M, Ptasznik A, Wlodarski P, Zhang Q, et al. (2005) Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab Invest 85: 1544-1554.
7. Silva RL, Wendel HG, (2008) MNK, EIF4E and targeting translation for therapy. Cell Cycle 7: 553-555.
8. Cargnello M, Roux PP, (2011) Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 75: 50-83.
9. Gibbons JJ, Abraham RT, Yu K, (2009) Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 36 (Suppl 3): S3-S17.
10. Jiménez-Rivera C, Avitzur Y, Fecteau AH, Jones N, Grant D, et al. (2004) Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant 8: 243-248.
11. Zaltzman JS, Prasad R, Chun K, Jothy S, (2005) Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus. Nephrol Dial Transplant 20: 1748-1751.
12. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV, (2004) Conversion to sirolimus: a successful treatment for post transplantation Kaposi's sarcoma. Transplantation 77: 760-762.
13. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, et al. (2005) Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352: 1317-1323.
14. Franz DN, Leonard J, Tudor C, Chuck G, Care M, et al. (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59: 490-498.
15. Hess G, Smith SM, Berkenblit A, Coiffier B, (2009) Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Oncol 36 (Suppl 3): S37-45.
16. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281.
17. Chan HY, Grossman AB, Bukowski RM, (2010) Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. Adv Ther 27: 495-511.
18. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, et al. (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 129: 747-759.
19. Teachey DT, Sheen C, Hall J, Ryan T, Brown VI, et al. (2008) mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 112: 2020-2023.
20. Choo AY, Blenis J, (2009) Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 8: 567-572.
21. Furic, Rong L, Larsson O, Koumakpayi IH, Yoshida K, et al. (2010) eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A 107: 14134-14139.
22. Panja D, Dagyte G, Bidinosti M, Wibrand K, Kristiansen AM, et al. (2009) Novel translational control in Arc-dependent long term potentiation consolidation in vivo. J Biol Chem 284: 31498-31511.
23. Zhang M, Fu W, Prabhu S, Moore JC, Ko J, et al. (2008) Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol Cell Biol 28: 6496-6509.